Why the study?
Do ACE inhibitors provide a favorable cost-benefit ratio by reducing hospitalizations in patients with cardiovascular diseases?
Population
Patients with cardiovascular diseases, including chronic heart failure, asymptomatic left ventricular…
Design
Review
Authors
Loading...
May support ACE inhibitor use in CV secondary prevention for cost savings; leaves open need for contemporary economic validation.
Do ACE inhibitors provide a favorable cost-benefit ratio by reducing hospitalizations in patients with cardiovascular diseases?
ACE inhibitors are economically beneficial in secondary prevention of cardiovascular diseases due to significant reductions in costly hospitalizations.
Franz X. Kleber (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: